Class I anti-CEA antibodies and uses thereof
The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.
Immunomedics, Inc.
A A C A C A C A A A C C A C A A A A A A A C C C C A C A A C A C A A A A A C C C A C A
A61P A61K C07K A61K C07K A61P C07K A61K A61K A61K C07K C07K A61K C07K A61K A61K A61K A61K A61K A61K A61K C07K C07K C07K C07K A61P C07K A61K A61K C07K A61K C07K A61K A61K A61K A61K A61P C07K C07K C07K A61K C07K A61P
inventional inventional additional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional additional inventional additional inventional inventional inventional inventional inventional additional additional additional additional inventional additional inventional inventional additional additional additional inventional inventional inventional inventional inventional inventional additional additional inventional additional inventional
Chien-Hsing David M. Hans J.
Chang Goldenberg Hansen